Global Incidence of Multiple Myeloma on the Rise
The global incidence of multiple myeloma is on the rise, particularly among men, people 50 years of age or older, and those from high-income countries.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Certain Blood Cancer Patients Do Not Seroconvert After a Third COVID-19 Vaccine Dose
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib. -
Measuring Circulating Tumor Cells at Diagnosis Can Improve Risk Stratification in Multiple Myeloma
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival. -
Data Support Daratumumab for Transplant-Eligible, Newly Diagnosed Multiple Myeloma
Final results from the GRIFFIN trial support adding daratumumab to induction, consolidation, and maintenance therapy for patients with newly diagnosed, transplant-eligible multiple myeloma. -
Clinical Trials Not Representative of Population With Leukemia, Multiple Myeloma
Women were underrepresented in AML trials, and men were underrepresented in MM and CML trials.
MULTIPLE MYELOMA NEWS
Infections Observed in Half of MM Patients Treated With Bispecific Antibodies
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
5 Factors That May Affect Multiple Myeloma Outcomes
Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
Loading... 
Loading...